HER2 positive breast cancer and its treatment with trastuzumab, where are we now?

Authors

  • Haris Lokvančić

DOI:

https://doi.org/10.37868/bes.v3i2.id239

Abstract

HER2-positive breast cancer is one of the most common types of female breast cancer around the world. This review summarizes information and results of HER2 -positive breast cancer trials and compares their results with the standards in Bosnia and Herzegovina. It is done based on a literature search on PubMed and Google Scholar. This review analyzed trastuzumab as a golden treatment standard for HER2 -positive cancer treatments. Trastuzumab is a monoclonal anti-human epidermal growth factor receptor antibody and besides its effect in the treatment of breast cancer, suggests the treatment with trastuzumab within 1 year. Bosnia and Herzegovina have also accepted standards and guidelines for the treatment of HER2 -positive breast cancer and they are in step with the latest achievements worldwide.

Downloads

Published

2022-12-30

How to Cite

[1]
H. Lokvančić, “ HER2 positive breast cancer and its treatment with trastuzumab, where are we now?”, Bioengineering Studies, vol. 3, no. 2, pp. 35–43, Dec. 2022.

Issue

Vol. 3 No. 2 (2022)

Section

Articles

License

Copyright (c) 2022 Haris Lokvančić

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

This journal permits and encourages authors to post items/PDFs submitted to the journal on personal websites or institutional repositories after publication, while providing bibliographic details that credit its publication in this journal.